These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9060162)

  • 1. Pyrolysis mass spectrometry: a predictor of clinical response to treatment in pulmonary opportunist mycobacterial infection: preliminary work with M. malmoense.
    Heginbothom ML; Magee JT
    Zentralbl Bakteriol; 1997 Jan; 285(2):291-8. PubMed ID: 9060162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment.
    Heginbothom ML
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):539-45. PubMed ID: 11409581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
    Research Committee of the British Thoracic Society
    Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary infection with Mycobacterium malmoense--a review of treatment and response.
    Banks J; Jenkins PA; Smith AP
    Tubercle; 1985 Sep; 66(3):197-203. PubMed ID: 4049531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy.
    Jenkins PA; Campbell IA; Banks J; Gelder CM; Prescott RJ; Smith AP
    Thorax; 2008 Jul; 63(7):627-34. PubMed ID: 18250184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to chemotherapy of pulmonary infection due to mycobacterium kansasii.
    Harris GD; Johnason WG; Nicholson D
    Bull Int Union Tuberc; 1976; 51(1):275-8. PubMed ID: 1030296
    [No Abstract]   [Full Text] [Related]  

  • 7.
    Kwon BS; Kim MN; Sung H; Koh Y; Kim WS; Song JW; Oh YM; Lee SD; Lee SW; Lee JS; Lim CM; Choi CM; Huh JW; Hong SB; Park S; Shim TS; Chong YP; Jo KW
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycobacterium malmoense infections in Scotland: an increasing problem.
    France AJ; McLeod DT; Calder MA; Seaton A
    Thorax; 1987 Aug; 42(8):593-5. PubMed ID: 3660312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A step forward in the evidence-based treatment of opportunist mycobacteria.
    Ormerod P
    Thorax; 2001 Mar; 56(3):163. PubMed ID: 11182003
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pulmonary infection due to Mycobacterium malmoense].
    Handrick W; Schwede I; Ebeling O; Wogawa B; Berthold F
    Pneumologie; 2005 Apr; 59(4):244-7. PubMed ID: 15944898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Research Committee, British Thoracic Society.
    Thorax; 1994 May; 49(5):442-5. PubMed ID: 8016763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycobacterium malmoense in the north-east of England.
    Connolly MJ; Magee JG; Hendrick DJ; Jenkins PA
    Tubercle; 1985 Sep; 66(3):211-7. PubMed ID: 4049533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of clinical efficacy of isoniazid and ethambutol in the treatment of nontuberculous mycobacteriosis based on in vitro susceptibility testing].
    Tsukamura M
    Kekkaku; 1989 Aug; 64(8):511-8. PubMed ID: 2811008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance.
    van Ingen J; Hoefsloot W; Mouton JW; Boeree MJ; van Soolingen D
    Int J Antimicrob Agents; 2013 Jul; 42(1):80-2. PubMed ID: 23664674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response.
    Banks J; Hunter AM; Campbell IA; Jenkins PA; Smith AP
    Thorax; 1983 Apr; 38(4):271-4. PubMed ID: 6867979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rifabutin in combination with clofazimine, isoniazid and ethambutol in the treatment of AIDS patients with infections due to opportunist mycobacteria. Groupe d'Etude et de Traitement des Infections à Mycobacteries Résistantes.
    Dautzenberg B; Truffot C; Mignon A; Rozenbaum W; Katlama C; Perronne C; Parrot R; Grosset J
    Tubercle; 1991 Sep; 72(3):168-75. PubMed ID: 1663282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of nontuberculous mycobacterial infections in pediatric patients.
    Levin RH; Bolinger AM
    Clin Pharm; 1988 Jul; 7(7):545-51. PubMed ID: 2843317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii.
    Harris GD; Johanson WG; Nicholson DP
    Am Rev Respir Dis; 1975 Jul; 112(1):31-6. PubMed ID: 1147382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapeutic regimens for nontuberculous mycobacterial infection based on in-vitro susceptibility test results].
    Tsukamura M; Yamori S
    Kekkaku; 1990 May; 65(5):349-57. PubMed ID: 2168003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of pulmonary disease caused by opportunist mycobacteria.
    Banks J
    Thorax; 1989 Jun; 44(6):449-54. PubMed ID: 2669223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.